Replies to post #190675 on Biotech Values

[DewDiligence]

Intarcia profile from last week’s SF Business Times is a good read:

http://www.bizjournals.com/sanfrancisco/blog/biotech/2015/04/intarcia-therapeutics-type-2-diabetes.html